CD8A and triple-negative breast carcinoma: In triple-negative breast cancer models, FGFR inhibition alters CAF secretory profiles and matrix remodeling, markedly increasing CD8+ T cell infiltration and suppressing tumor growth, supporting the rationale for FGFR-TKI and ICI combination therapy [134].